Oral Anticoagulant Comparisons    body {font-family: 'Open Sans', sans-serif; padding-left: 10px;}

### Oral Anticoagulant Comparisons

table.tableizer-table { font-size: 12px; border: 1px solid #CCC; font-family: Arial, Helvetica, sans-serif; } .tableizer-table td { padding: 4px; margin: 3px; border: 1px solid #CCC; } .tableizer-table th { background-color: #104E8B; color: #FFF; font-weight: bold; }

|  | Warfarin | Dabigatran | Rivaroxaban | Apixaban | Edoxaban |
| --- | --- | --- | --- | --- | --- |
| Target | IIa, Vlla, IXa, Xa | IIa | Xa | Xa | Xa |
| Peak effect | 4-5 days | 1.5-3 h | 2-4 h | 1-3 h | 1-2 h |
| Half-life | 40 h | 12-17 h | 5-9 h | 9-14 h | 9-11 h |
| Renal elim. | None | 80% | 33% | 25% | 35-50% |
| Dialyzable | No | Yes | No | No | No |
| Interactions | Many | P-gp | 3A4, P-gp | 3A4, P-gp | 3A4, P-gp |
| Monitoring | Yes | No | No | No | No |
| Antidote | Vitamin K | Praxbind | No | No | No |
| Lab measure | INR | aPTT(qual) | PT (qual) | No data | PT (qual) |

  

P-gp (p glycoptoyein) Cove CL,Hylek EM. J Am Heart Association 2013; 2:e000136.  
3A4 (cytochrome P450 3A4)  
qual (qualitative)